Athenex

171 articles about Athenex

• Athenex Pharma Solutions, An Athenex Company, Launches Three New Sterile Injectable Products From Its 503(B) Facility

  8/10/2017

• Athenex Announces Recent Product Launches In Commercial Business

  8/1/2017

• Athenex To Report Second Quarter 2017 Earnings Results On August 14, 2017

  7/31/2017

• Athenex Gets Tax Incentives For Its New $208 Million New York Facility

  7/28/2017

• Athenex Announces Commencement Of Patient Enrollment For Oraxol-Plus-Ramucirumab Phase Ib Clinical Trial In Gastric Cancer

  7/19/2017

• Athenex Division Receives FDA Clearance To Import Sodium Bicarbonate 8.4% Injection To Address U.S. Drug Shortage

  7/12/2017

• Athenex Announces Submission Of Investigational New Drug Application Of Oraxol To Chinese FDA

  7/5/2017

• Athenex Announces Closing Of Initial Public Offering And Full-Exercise Of Over-Allotment Option

  6/20/2017

• Athenex, A US-China Cancer Company, Stages $66 Million U.S. IPO

  6/16/2017

• Athenex Announces Pricing Of Initial Public Offering

  6/14/2017

• Athenex And Its Partner, Guangzhou Xiangxue Pharma, Announced Chinese FDA IND Approval To Begin Clinical Trials Of KX-02 Tablet For Glioblastoma

  5/25/2017

• With Plans for U.S. and China Manufacturing Plants, Athenex Gears Up for $100 Million IPO

  5/16/2017

• Athenex, A U.S.-China Biopharma, Starts U.S. Trial Of Oral Chemotherapy

  3/29/2017

• Athenex Announces The U.S. FDA Allowance Of The Investigational New Drug Application Of Oratopo, A Combination Of HM30181A And Oral Topotecan For The Treatment Of Advanced Cancer

  3/29/2017

• Athenex Announces The Promotion Of Jeffrey M. Yordon To The Position Of Chief Operating Officer

  3/1/2017

• Athenex Appoints Veteran J. Nick Riehle As Chief Financial Officer

  2/27/2017

• Athenex And Eli Lilly Enter Clinical Collaboration Agreement

  11/18/2016

• Athenex And BeiJing Sciecure Pharmceutical Announce Binding Agreement To Launch And Market Five Injectable Pharmaceutical Products In North America

  10/25/2016

• Athenex Announces Xiangxue Pharmaceutical, Its KX-02 Development Partner In China, Has Achieved A Regulatory Milestone In That Territory

  10/18/2016

• Athenex And SunGen Pharmaceuticals Enter Into U.S. Joint Venture Agreement For A Portfolio Of 7 Approved Pharmaceutical Products

  9/27/2016